| Pharmaceutical Information |
| Drug Name |
Tafluprost |
| Drug ID |
BADD_D02108 |
| Description |
A prostaglandin analogue ester prodrug used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. Chemically, tafluprost is a fluorinated analog of prostaglandin F2-alpha. Tafluprost was approved for use in the U.S. on February 10, 2012. |
| Indications and Usage |
Tafluprost is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. |
| Marketing Status |
approved |
| ATC Code |
S01EE05 |
| DrugBank ID |
DB08819
|
| KEGG ID |
D06274
|
| MeSH ID |
C485333
|
| PubChem ID |
9868491
|
| TTD Drug ID |
D04LCQ
|
| NDC Product Code |
82584-609; 61556-080; 65035-137; 54893-0021; 63190-0590; 76397-013; 65302-062; 68245-0012; 75872-0001; 66993-429; 0781-6184; 70390-0001; 17478-609 |
| UNII |
1O6WQ6T7G3
|
| Synonyms |
tafluprost | 1-methylethyl (5Z)-7-((1R,2R, 3R,5S)-2-((1E)-3,3-difluoro-4-phenoxy -1-butenyl)-3,5-dihydroxycyclopentyl)-5-heptenoate | AFP-168 |
|
| Chemical Information |
| Molecular Formula |
C25H34F2O5 |
| CAS Registry Number |
209860-87-7 |
| SMILES |
CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC=C2)(F)F)O)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
